Drug Profile
BIIB 076
Alternative Names: BIIB-076Latest Information Update: 29 Apr 2022
Price :
$50
*
At a glance
- Originator Neurimmune Therapeutics
- Developer Biogen
- Class Antidementias; Monoclonal antibodies
- Mechanism of Action Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alzheimer's disease
Most Recent Events
- 29 Apr 2022 BIIB 076 is still in phase I trials for Alzheimer's-disease in USA (IV, Infusion) (Biogen pipeline, April 2022)
- 03 Mar 2020 Biogen completes a phase I trial in Alzheimer's disease in USA (NCT03056729)
- 03 Mar 2020 BIIB 076 is still in phase I trials for Alzheimer's disease in USA (Neurimmune Therapeutics website, March 2020)